Baidu
map

JCO:恶性胸膜间皮瘤患者预防性照射:开放标签,多中心,III期随机临床试验

2019-03-30 海北 MedSci原创

在诊断或治疗后,恶性胸膜间皮瘤(MPM)患者对胸壁进行预防性放射治疗已成为整个欧洲的一种普遍做法,但是这种治疗的疗效尚不确定。

诊断或治疗后,恶性胸膜间皮瘤(MPM)患者对胸壁进行预防性放射治疗已成为整个欧洲的一种普遍做法,但是这种治疗的疗效尚不确定。在最近的一项研究中,研究人员尝试确定预防性放疗在降低MPM手术后胸壁转移(CWM)发生率方面的效果。

在进行胸壁手术后,MPM患者被随机分配到接受预防性放疗(在手术后42天内)或不进行放疗的组。胸廓切开术,穿刺活检和留置胸膜导管患者被排除在外。预防性放疗以21Gy的剂量连续三个工作日以三个部分递送,使用适于最大化从皮肤表面到胸膜的管道覆盖的单个电子场。

该试验的主要结果是随机分配后6个月内CWM的发生率,在意向治疗人群中进行评估。分层因素包括上皮样组织学和给予化疗的意图。

结果显示,2012年7月30日至2015年12月12日期间,研究人员从54个中心招募了375名患者,其被随机分配接受预防性放疗(n = 186)或无预防性放疗(n = 189)。参与者在基线时匹配良好。

预防性放疗组与无放疗组之间6个月CWM发生率无显着差异(分别为[%]:6 [3.2] v 10 [5.3];优势比为0.60; 95%CI,0.17到1.86; P = .44)。皮肤毒性是预防性放疗组中最常见的放疗相关不良事件,96名患者(51.6%)出现1级放射性皮炎; 19名(10.2%)患者和1名(0.5%)患者分别遭受2级和3级放射性皮炎。

因此,对于MPM患者,常规使用预防性照射对胸壁手术部位没有作用。


原始出处:

Bayman N et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. JCO, 2019; doi: 10.1200/JCO.18.01678. 


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-06-14 lifestar
  5. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-08-02 juliusluan78
  6. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
    2019-12-22 lidong40
  7. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1903976, encodeId=484819039e6f4, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Tue Jun 25 20:49:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661384, encodeId=b69a166138418, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Fri Aug 23 03:49:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034804, encodeId=85632034804e2, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Aug 04 03:49:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666278, encodeId=19c916662e8f7, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Fri Jun 14 06:49:00 CST 2019, time=2019-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916092, encodeId=c95419160921a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Aug 02 18:49:00 CST 2019, time=2019-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891585, encodeId=38271891585e8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Dec 22 19:49:00 CST 2019, time=2019-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579810, encodeId=5d1615e981036, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Apr 01 00:49:00 CST 2019, time=2019-04-01, status=1, ipAttribution=)]

相关资讯

NCCN临床实践指南:恶性胸膜间皮瘤(2019.V1)

2019年2月,美国国家综合癌症网络(NCCN)发布了恶性胸膜间皮瘤指南2019年第1版,指南主要内容涉及: 更新摘要 初步评估 术前评估 临床分期Ⅰ-Ⅲ和上皮或混合组织学、评估 临床分期Ⅳ或临床上肉瘤样的组织学 临床分期Ⅰ-Ⅲ手术治疗 系统治疗原则 维持治疗的原则 手术治疗原则 放疗原则 肿瘤分期

Thorax:恶性胸膜间皮瘤早期专科姑息治疗对生活质量的影响

对于在提供SPC的中心进行治疗的患者,MPM诊断后不久常规转诊至SPC并没有作用。

恶性胸膜间皮瘤研究进展

恶性胸膜间皮瘤(MPM)是一种少见的起源于胸膜间皮细胞的原发肿瘤,多发生在50~70岁,男性多见。其发病率较低,占胸膜肿瘤的5%,仅占全部恶性肿瘤的0.02%~0.04%[1]。该病起病隐匿,接触石棉为首要致病因素,与其细胞毒性可诱导产生活性氧(ROS)导致氧化应激作用有关[2]。最新研究显示石棉诱导DNA甲基化修饰与发病密切相关[3]。其他致病因素包括矿物纤维、电离辐射和猿猴空泡病毒40(SV4

J Clin Oncol:重磅! ASCO恶性胸膜间皮瘤的诊疗指南

恶性胸膜间皮瘤(MPM)是一种罕见疾病,发病率逐年上升,但预后很差。1月18日在JCO在线发布了《恶性胸膜间皮瘤ASCO临床实践指南》,肿瘤资讯对该指南进行编译,希望对您有所借鉴。

NCCN临床实践指南:恶性胸膜间皮瘤(2018.V1)

2018年2月,美国国家综合癌症网络(NCCN)发布了恶性胸膜间皮瘤指南2018年第1版,指南主要内容涉及: 更新摘要 初步评估 术前评估 临床分期Ⅰ-Ⅲ和上皮或混合组织学、评估 临床分期Ⅳ或临床上肉瘤样的组织学 临床分期Ⅰ-Ⅲ手术治疗 维持治疗的原则 化疗原则 手术治疗原则 放疗原则 肿瘤分期

2018 BTS指南:恶性胸膜间皮瘤的调查和管理

2018年英国胸科协会(BTS)发布了恶性胸膜间皮瘤的调查和管理指南,本文的主要目的是针对疑似恶性胸膜间皮瘤的调查以及确诊患者的后续管理提供详细的循证指导。

Baidu
map
Baidu
map
Baidu
map